Biotech company Emergex Vaccines Holding Limited has raised over $11 million in a Series A round led by Singapore-based venture capital firm Vickers Venture Partners, according to a statement. Founded in 2016, Emergex, a UK-based biotechnology company, claims to have developed vaccines to address some of the world’s most immediate health threats such as Dengue Fever, Zika, Ebola, pandemic flu and serious intra-cellular bacterial infections.